Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET-study
2024-518985-29-02Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 PSMA I&T and radium-223 dichloride in prostate cancer (PCa), sponsored by Amsterdam University Medical Center. Primary endpoints: Feasibility and safety of alternating Radium-223 and 177Lu-PSMA radioligand therapy and Feasibility threshold for treatment schedule. Started Dec 2024; status: completed.
02
Drugs
lutetium Lu 177 PSMA I&Tradium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-518985-29-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518985-29-02.